INCYTE CORPORATION

ZYNYZ

Manufacturer:

INCYTE CORPORATION

Zynyz HCPCS:

J9345

HCPCS Code Descriptor:

Injection, retifanlimab-dlwr, 1 mg

Category:

J Code

Zynyz NDCs:

50881-0006-03

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Zynyz CPT Codes:

Potential CPT administration codes for Zynyz can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zynyz:

ZYNYZ is an Oncology drug manufactured by Incyte and administered via the Intravenous route of administration. The J Code: J9345 is aligned to the drug ZYNYZ.

ZYNYZ is a monoclonal antibody recommended for the treatment of metastatic or intractable advanced Merkel cell carcinoma. It works by binding programmed death receptor-1 (PD-1) on the surface of T-cells. When ZYNYZ (J9345) binds PD-1, the immune system can more efficiently attack cancer cells. ZYNYZ is most commonly indicated for use in adults who have aggressive Merkel cell carcinoma. Patient assistance for this medication can be found through the IncyteCARES program.

ACCESS PRICING AND MORE BY REGISTERING

J9345 Added Date:

October 1, 2023

J9345 Effective Date:

October 1, 2023

J9345 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Zynyz billing and coding information.
Zynyz patient assistance information can be found through IncyteCares at the URL: https://www.incytecares.com/
ZYNYZ prescribing information can be found at the link below:
Information regarding ZYNYZ’s side effects can be found at MedlinePlus

BuyandBill.com Drug Alert: